| Early experience with enteric-coated mycophenolate sodium in de novo kidney transplant recipients. | |
| | |
MedLine Citation:
|
PMID: 15964340 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
INTRODUCTION: We sought to evaluate the efficacy of enteric-coated mycophenolate sodium (EC-MPS) and the gastrointestinal (GI) adverse events in de novo kidney transplant recipients. METHODS: This noncontrolled, retrospective review includes 22 de novo kidney transplant recipients. All patients received a standard course of basiliximab and were maintained on triple-drug therapy with EC-MPS, cyclosporine microemulsion (CsA), and prednisolone. The follow-up lasted 7.9 +/- 1.2 months. The incidence of GI adverse effects were compared with those of historical mycophenolate mofetil (MMF) studies. RESULTS: The serum creatinine was maintained within 1.4 +/- 0.7 mg/dL. The 2-hour CsA postdose level was 1080 +/- 327 ng/mL initially and gradually tapered to 851 +/- 435 ng/mL. The daily EC-MPS dose was 1404 +/- 180 mg initially and gradually tapered to 1098 +/- 288 mg. The GI adverse effects at the daily dose of EC-MPS 1422 +/- 126 mg included dyspepsia 27%, acid regurgitation 18.2%, epigastralgia 9%, nausea 9%, vomiting 4.5%, and poor appetite 4.5%. In comparison those from historical MMF 2 g/d studies included dyspepsia 3.1% to 40%, epigastralgia 10%, nausea 3.7% to 34%, and vomiting 0.6% to 10.7%. CONCLUSION: Immunosuppression with CsA, EC-MPS, and steroids maintains stable graft functions. Minimal dose reduction of EC-MPS decreases GI adverse events but without significance. EC-MPC and MMF have respective GI side effects; they can be used alternatively in patients with individual GI intolerance. |
| | |
Authors:
|
H-R Chang; C-C Lin; J-D Lian |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Transplantation proceedings Volume: 37 ISSN: 0041-1345 ISO Abbreviation: Transplant. Proc. Publication Date: 2005 Jun |
Date Detail:
|
Created Date: 2005-06-20 Completed Date: 2005-10-25 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0243532 Medline TA: Transplant Proc Country: United States |
Other Details:
|
Languages: eng Pagination: 2066-8 Citation Subset: IM |
Affiliation:
|
Division of Nephrology, Department of Internal Medicine, Chung-Shan Medical University, Taichung, Taiwan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Cyclosporine
/
therapeutic use Drug Therapy, Combination Hematocrit Humans Immunosuppressive Agents / administration & dosage, adverse effects, therapeutic use Kidney Transplantation / immunology* Mycophenolic Acid / administration & dosage, analogs & derivatives*, therapeutic use Platelet Count Prednisolone / therapeutic use Retrospective Studies Tablets, Enteric-Coated |
| Chemical | |
Reg. No./Substance:
|
0/Immunosuppressive Agents; 0/Tablets, Enteric-Coated; 128794-94-5/mycophenolate mofetil; 24280-93-1/Mycophenolic Acid; 50-24-8/Prednisolone; 59865-13-3/Cyclosporine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Diffuse vascular damage in a transplanted kidney: an indication for nuclear magnetic resonance?
Next Document: The cost-effectiveness of basiliximab induction in "old-to-old" kidney transplant programs: Bayesian...